# Andrew D Chantry

List of Publications by Year
in descending order



| 39 | 1,173 | 567281 15 | 377865 34 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 42 | 42 | 42 | 1615 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | What Can Patient Narratives Reveal to Us About the Experience of a Diagnosis of Myeloma? A Qualitative Scoping Review. Journal of Patient Experience, 2022, 9, 237437352210791. | 0.9 | 3 |
| 2 | Multiple myelomaâ€"A painful disease of the bone marrow. Seminars in Cell and Developmental Biology, 2021, 112, 49-58. | 5.0 | 10 |
| 3 | Bone Pain in Multiple Myeloma (BPMM)â€"A Protocol for a Prospective, Longitudinal, Observational Study. Cancers, 2021, 13, 1596. | 3.7 | 5 |
| 4 | Assessment of droplet digital polymerase chain reaction for measuring BCRâ€ABL1 in chronic myeloid leukaemia in an international interlaboratory study. British Journal of Haematology, 2021, 194, 53-60. | 2.5 | 10 |
| 5 | Myeloma Bone Disease: The Osteoblast in the Spotlight. Journal of Clinical Medicine, 2021, 10, 3973. | 2.4 | 7 |
| 6 | Pre-clinical investigation of inhibition of the DNA damage response as a targetted therapy in myeloproliferative neoplasms shows synergism of ATR inhibitors with standard-of-care treatment.. , 2021, 3, . | | 0 |
| 7 | The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma. Cancers, 2021, 13, 5687. | 3.7 | 6 |
| 8 | Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo. Blood, 2021, 138, 1594-1594. | 1.4 | 1 |
| 9 | ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation. Stem Cell Research and Therapy, 2020, 11, 516. | 5.5 | 25 |
| 10 | The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene, 2020, 39, 5001-5014. | 5.9 | 17 |
| 11 | Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. Journal of Bone Oncology, 2019, 17, 100243. | 2.4 | 15 |
| 12 | TGFÎ² Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. Journal of Bone and Mineral Research, 2019, 34, 2311-2326. | 2.8 | 14 |
| 13 | A university â€“ Led initiative to promote voluntary non-remunerated blood donation in a developing country. Transfusion and Apheresis Science, 2019, 58, 674-679. | 1.0 | 6 |
| 14 | Mechanisms and treatment of bone pain in multiple myeloma. Current Opinion in Supportive and Palliative Care, 2019, 13, 408-416. | 1.3 | 16 |
| 15 | Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international interâ€laboratory study: Is it ready for primetime use?. Cytometry Part B - Clinical Cytometry, 2019, 96, 201-208. | 1.5 | 15 |
| 16 | Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. Journal of Bone and Mineral Research, 2019, 34, 783-796. | 2.8 | 22 |
| 17 | Mesenchymal lineage cells and their importance in B lymphocyte niches. Bone, 2019, 119, 42-56. | 2.9 | 13 |
| 18 | New agents in the Treatment of Myeloma Bone Disease. Calcified Tissue International, 2018, 102, 196-209. | 3.1 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. PLoS ONE, 2018, 13, e0199517. | 2.5 | 9 |
| 20 | Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018. Blood, 2018, 132, 4743-4743. | 1.4 | 1 |
| 21 | Comparison of the CELLEXâ„¢ and UVARâ€XTSâ„¢ closedâ€system extracorporeal photopheresis devices in the treatment of chronic graftâ€versusâ€host disease. Journal of Clinical Apheresis, 2017, 32, 462-473. | 1.3 | 7 |
| 22 | Low-dose methotrexate in myeloproliferative neoplasm models. Haematologica, 2017, 102, e336-e339. | 3.5 | 9 |
| 23 | The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-Î±]Pyridin-3-yl)-Ethyl-Bisphosphonate). Journal of Bone and Mineral Research, 2017, 32, 1860-1869. | 2.8 | 19 |
| 24 | Guidelines for the use of imaging in the management of patients with myeloma. British Journal of Haematology, 2017, 178, 380-393. | 2.5 | 101 |
| 25 | Researching surviving cancer and sexuality using visual methods: a reflection on research rationale and negotiating ethical issues. Families, Relationships and Societies, 2015, 4, 483-492. | 0.9 | 2 |
| 26 | Time to redefine Myeloma. British Journal of Haematology, 2015, 171, 1-10. | 2.5 | 18 |
| 27 | Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma. British Medical Bulletin, 2015, 113, 15-30. | 6.9 | 16 |
| 28 | NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. PLoS ONE, 2015, 10, e0119546. | 2.5 | 36 |
| 29 | Myeloma bone disease: pathogenesis, current treatments and future targets. British Medical Bulletin, 2014, 111, 117-138. | 6.9 | 61 |
| 30 | A Small Molecule Modulator of Prion Protein Increases Human Mesenchymal Stem Cell Lifespan, Ex Vivo Expansion, and Engraftment to Bone Marrow in NOD/SCID Mice. Stem Cells, 2012, 30, 1134-1143. | 3.2 | 31 |
| 31 | Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo. PLoS ONE, 2012, 7, e35830. | 2.5 | 13 |
| 32 | Spontaneous splenic rupture: an unusual presentation of CML. BMJ Case Reports, 2011, 2011, bcr0220113879-bcr0220113879. | 0.5 | 9 |
| 33 | Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research, 2010, 25, 2633-2646. | 2.8 | 129 |
| 34 | Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma. Journal of Bone and Mineral Research, 2009, 24, 425-436. | 2.8 | 230 |
| 35 | Apomineâ„¢, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. International Journal of Cancer, 2007, 120, 1657-1663. | 5.1 | 20 |
| 36 | Long-Term Outcomes of Myeloablation and Autologous Transplantation of Relapsed Acute Myeloid Leukemia in Second Remission: A British Society of Blood and Marrow Transplantation Registry Study. Biology of Blood and Marrow Transplantation, 2006, 12, 1310-1317. | 2.0 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Bortezomib reduces serum dickkopfâ€1 and receptor activator of nuclear factorâ€Î°B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British Journal of Haematology, 2006, 135, 688-692. | 2.5 | 217 |
| 38 | Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.. Blood, 2006, 108, 506-506. | 1.4 | 1 |
| 39 | Myeloma bone disease â€“ pathogenesis of bone destruction and therapeutic strategies. , 0, , 96-109. | | 0 |